EMEA-000380-PIP04-10 - paediatric investigation plan

recombinant human monoclonal antibody to human interleukin 17A (AIN457)

Key facts

• Active substance:
  recombinant human monoclonal antibody to human interleukin 17A (AIN457)
• Therapeutic area:
  Ophthalmology
• Decision number:
  P/237/2010
• PIP number:
  EMEA-000380-PIP04-10
• Pharmaceutical form(s):
  Powder for solution for injection
• Condition(s) / indication(s):
  Treatment of chronic non-infectious uveitis
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  26/11/2010
• Compliance check done:
  No

Decision

P/237/2010: EMA decision of 26 November 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for recombinant human monoclonal antibody to human Inter...

Adopted Reference Number: EMA/703761/2010